Medical Research

Community information
The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.
  • [UPDATE]

    Special Guest Terry Kenakin Ph.D. will be taking part in our LIVE Q&A session answering your questions!

    [ABOUT THIS WEBINAR]

    Ligand bias is a well-established concept in the GPCR research field that is beginning to emerge as a means to optimize GPCR targeted drug design. Most approved medications that target GPCRs act as either agonists or antagonists of heterotrimeric G protein and β-arrestin pathways. In many cases, this classical signaling paradigm leads to both efficacy and on-target adverse events. Biased GPCR ligands have the ability to activate or inhibit with greater selectivity one of the two downstream effector proteins and its subsequent signaling cascades. The goal of this webinar is to illustrate in vitro characterization of GPCR ligand bias and its translation to in vivo proof-of concept using TRV027, an AT1R modulator, as an exemplar biased ligand.

    > What attendees will learn about?

    • Review of GPCR signaling
    • Introduction to concept of ligand bias and quantification thereof
    • Utility of 2nd messenger assays in GPCR drug discovery
    • Pre-clinical biased ligand proof-of-concept
  • The Asia Pacific is the third largest pharmaceutical market in the world after North America and Europe, with generics being the major driver for the pharmaceutical industry in this region, aided by factors such as the aging population and impending expiry of patented drugs. It is a necessity for pharmaceutical companies to be aware of the key trends in the APAC generics market and maximise the market opportunities in order to remain relevant.

    In today’s rapidly evolving business landscape, pharmaceutical companies are also starting to realise the importance of the customer experience as a key differentiator. With a gradual shift from product to the customer, the pharmaceutical industry needs to keep up with other industries in terms of providing the perfect digital customer experience. A well-executed digital strategy is essential for today’s pharmaceutical companies to better connect with their clients.

    Join us as we discuss these and other key topics.
  • Cell lines remain the workhorses of laboratory research, both in academic and industrial settings. This webinar will focus on best practice in selecting and maintaining cell lines for research, to ensure research outputs are relevant and reproducible. Features of cell lines that might be used in selection will be discussed. This will include monolayer or suspension culture; passage number; doubling time; immortalisation; karyotype; receptors; expression profiling and use of bioinformatics tools like the cancer cell line encyclopaedia. Using breast cancer as an exemplar, I will discuss more specifically how to choose the most relevant cell line model to address a particular research question. Finally I will describe how to use (and access) human material to help develop more clinically relevant cell culture systems to model human disease and the role that biobanks play in this process.
  • Cell lines remain the workhorses of laboratory research, both in academic and industrial settings. This webinar will focus on best practice in selecting and maintaining cell lines for research, to ensure research outputs are relevant and reproducible. Features of cell lines that might be used in selection will be discussed. This will include monolayer or suspension culture; passage number; doubling time; immortalisation; karyotype; receptors; expression profiling and use of bioinformatics tools like the cancer cell line encyclopaedia. Using breast cancer as an exemplar, I will discuss more specifically how to choose the most relevant cell line model to address a particular research question. Finally I will describe how to use (and access) human material to help develop more clinically relevant cell culture systems to model human disease and the role that biobanks play in this process.
  • Multiplexed protein assays have tremendous potential in clinical diagnostics, in particular measurement of proteins in plasma or serum derived from circulating blood. The dynamic range of protein concentration in these samples, and the dominance of very high abundance proteins such as albumin and immunoglobulins, make measurement of low concentration proteins impossible without some type of enrichment approach. This workshop will discuss the benefits of using Seppro® protein depletion columns in sample preparation for multiplexed LC-MS protein clinical assays.
  • Vitamin E is a powerful antioxidant, an essential nutrient needed to maintain cellular structures and functions, thus helping support health. However, intake still remains low among consumers globally. There is an ongoing discussion about the optimal vitamin E status in healthy populations and its role in maintaining liver and brain function outside of nutritional recommendations.

    New and ongoing research suggests that vitamin E at higher doses may help maintain tissue function in specific risk groups, such as age-related macular degeneration, Alzheimer’s disease and non-alcoholic fatty liver. Applications like these require the advice and supervision of health care professionals. It is important to revisit both the required doses and safety for targeted vitamin E intakes for these conditions. Further research will be required to support qualified health claims for mitigating the outcomes of these diseases.

    Join the latest webinar in our series on research related to vitamin E. Hear our speakers Prof. Jeffrey Blumberg and DSM’s Prof. Manfred Eggersdorfer and Jacob Bauly present their latest findings on vitamin E safety and its implications on the recommended intake across different life stages and conditions.
  • Vitamin E is a powerful antioxidant, an essential nutrient needed to maintain cellular structures and functions, thus helping support health. However, intake still remains low among consumers globally. There is an ongoing discussion about the optimal vitamin E status in healthy populations and its role in maintaining liver and brain function outside of nutritional recommendations.

    New and ongoing research suggests that vitamin E at higher doses may help maintain tissue function in specific risk groups, such as age-related macular degeneration, Alzheimer’s disease and non-alcoholic fatty liver. Applications like these require the advice and supervision of health care professionals. It is important to revisit both the required doses and safety for targeted vitamin E intakes for these conditions. Further research will be required to support qualified health claims for mitigating the outcomes of these diseases.

    Join the latest webinar in our series on research related to vitamin E. Hear our speakers Prof. Jeffrey Blumberg and DSM’s Prof. Manfred Eggersdorfer and Jacob Bauly present their latest findings on vitamin E safety and its implications on the recommended intake across different life stages and conditions.
  • Join us on June 22nd for a special Corning-sponsored webinar presented by ATCC®.

    Abstract:
    Animal cell lines are important in vitro systems and tools for scientists in diverse disciplines such as basic cell biology, genetic mapping, gene expression and gene therapy. Cell line authentication and characterization are crucial in these activities, yet they are underappreciated by most research scientists. Over the years numerous cell lines have been shown to be misidentified due, in part, to poor techniques and inadequate verification of cell line authenticity. Technological advances have given rise to improved capabilities. Cell line authentication now requires a comprehensive strategy that employs several complementary technologies for systematic testing for morphology, microbial contaminations, cellular identity/cross-contamination as well as functionality. The validity of conclusions drawn from research data is dependent on consistent and unequivocal verification of cell line identity and function. It is estimated that the financial loss incurred by poorly characterized or misidentified cell lines is in the millions of dollars. An overview of the current technologies used to authenticate cell lines will be presented.

    Speaker Bio:
    Dr. Yvonne A. Reid joined ATCC in 1980 and during the mid-1980’s her research focused on the use of DNA hypervariable probes for the intraspecies identification of cell lines. The evolution of this work has led to the implementation of routine screening of all human cell lines by STR analysis. She co-chaired the ATCC SDO committee on the Development Consensus Standard on the Authentication of Human Cell Lines: Standardization of STR profiling. Dr. Reid has more than 30 years of experience in cell biology, immunology and molecular biology. As Collection Scientist for the Cell Biology Program for over 10 years, she was responsible for acquisition of new animal cell lines and hybridomas into the Cell Biology General Collection.
  • The cost of solvent disposal can be just as high or higher than the cost of purchasing solvent. Less expensive technical grade solvent can be purified by distillation to achieve the purity necessary for academic and industrial applications. Solvent reclamation, recycling and purification with a BUCHI Industrial Rotavapor® is not only efficient but it pays for itself after one year. Join us to discover ways to better manage or develop your own in-house solvent disposal/ recycling program and the benefits of this type of program.
    During this webinar we will discuss:
    •Solutions to improve the purity of technical grade solvents
    •Solvent reclamation and reselling
    •Solvent recycling
  • Learn how to set your institution up for success by having the correct people, processes, and technology in place to address the serious problem of drug diversion. In this webinar you will:
    •Learn proper policies and procedures to prevent diversion across multiple areas in your facility
    •Understand common gaps in diversion management in procedural areas and pharmacy
    •Identify opportunities to collaborate with different departments to protect your patients from the harms of diversion.

    PLEASE BE SURE TO TEST YOUR SYSTEM'S COMPATIBILITY ON THE BRIGHTTALK PLATFORM PRIOR TO ATTENDING THE EVENT TO ENSURE AN OPTIMAL EXPERIENCE. SMARTPHONES MAY NOT WORK DURING THE LIVE EVENT, BUT WILL WORK IN THE RECORDED PLAYBACK MODE AFTER THE EVENT.
  • Learn why encapsulation is important and how it can be accomplished with BUCHI products. A complete overview of encapsulation will be presented, from matrix to core and shell capsules. The different types of materials used in spray drying verses those used in prilling by vibration will be reviewed. Application areas to be presented include cells, probiotic foods, and pharmaceutical. Release mechanisms and profiles of the encapsulated materials will be shared.
  • IBM SPSS Modeler extends the value of Big Data through algorithms purpose-built for massive scale analytics, introduces geospatial analytics and continues to expand accessibility to and usability of advanced analytics.

    Join our Technical Solutions expert, Dusan Magula, for a demonstration with live Q&A and learn about:

    * SPSS Modeler Personal Edition that puts predictive power in the hands of an individual user
    * New algorithms for Big Data and Geospatial analysis
    * Predictive Extensions that bring the flexibility and power of R to SPSS Modeler users “code-free”
  • The spread of counterfeit and substandard medicines is a global threat to public health. The sources of most counterfeit medicines found globally were traced to Asia. Although many of these products were found outside the region, many Asian countries are at high risk of exposure to them. There is a need for easy and affordable tools for screening medicines. Handheld Raman devices have gained increasing interest as such tools. Many of the devices available share some advantages in the detection of counterfeit medicines but there are challenges in the detection of substandard products. Fixed-dose combination medicines present even greater challenges.
  • Thermal analysis instruments must always be accurate, true and precise in order to deliver reproducible results within a given range. Performing a calibration determines whether your module is delivering correctly measured values or whether it needs an adjustment. The different parameters that must be calibrated are temperature, heat flow, mass, length and modulus. In this Webinar, we will discuss the basics of calibration and adjustment in thermal analysis whilst offering some useful tips and hints.
  • Yes? No? Maybe? Join Dr. James Hnatyszyn on May 26 at 9 AM, Phoenix time to learn more about the impact of NGS on research and clinical diagnostics. Dr. Hnatyszyn is the Senior Director, Companion Diagnostics, Global Laboratory Operations at Ventana Medical Systems Inc. He will review the available NGS technologies and address key issues to consider when using these technologies.
  • Accelerating Pharma R&D with Novel MS Applications for High Throughput Screening (HTS), Drug Imaging and Integrating MS and NMR data for high confidence structure verification of small molecules.

    This webinar will introduce novel MS and NMR solutions and its applications in pharmaceutical research:

    > NMR Spectroscopy and Mass Spectrometry are two fundamental techniques for small molecule structure verification. Bruker FUSION-SV - a new software solution for comprehensive fully automated small molecule structure verification – simplifies and accelerates the drug design and discovery phases in the pharmaceutical industry significantly. The new Bruker FUSION-SV™ is a software solution integrating high resolution accurate mass (HRAM) data and complementary NMR data, into one result - increasing significantly the specificity and throughput for small organic molecule structure verification. Synthesis chemists will get a prompt result without being an expert spectroscopist.

    > Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) instruments are ideally suited for high throughput screening (HTS) in drug discovery. Not only speed, simplicity and robustness are the convincing arguments for MALDI-TOF MS but the inherent strength of a label- and solvent-free technique. The webinar will explain the technique and advantages of MALDI-TOF MS and present automation solutions for highest throughput and speed (less than 1 second per sample).

    > Finally the webinar will describe how the MALDI technology is used for small molecule imaging when coupled to modern 7 T (Tesla) FT-MS instrumentation. Drugs and metabolites can be visualized and distinguished one from the other directly measured from tissue samples. These results can be linked with histological information derived from the very same tissue, giving new insights into drug action and toxicity.
  • Whether you are an experienced researcher or just starting out in your research career, you’ve heard about how important search engine optimization (SEO) is in today’s ocean of online media. You probably know that most researchers have concerns about how “discoverable” their work is amidst the global acceleration of research output in recent years and the increasing sophistication of search engines. Publishing in high-impact journals helps your work get discovered – it’s true - but there are also approaches that you can employ while writing to craft your work for increased online discoverability once it is published. Jamie Wielgus, Associate Editor, Health Sciences, Wiley, and Kris Bishop, Marketing Manager, Wiley, present on some of these techniques and the factors at work behind discoverability with the goal of helping authors take action at the writing stage to best position their articles to be found and read.

    In this interactive 60 minute webinar Jamie and Kris will cover the following topics:

    - The Abstract: What is it for? How should it be structured? Examples?
    - The Title: What makes a good title? Examples?
    - Keywords: How should authors use keywords to be found by readers using today’s search engines?
    - Search Engine Optimization (SEO): Latest advice on SEO? How can research be optimized for search?
    - Discoverability: Pulling it all together!
    - Questions and Feedback
  • Microbiological methods play a critical role in ensuring safety and efficacy of drugs and biologics. Most microbiological methods are described in compendia and do not need method validation. However, rapid microbiological methods and other alternate methods require full validation. Due to large inherent variability and complexity of microbiological methods, there are challenges in validation of such methods. This webinar will discuss, ways of performing validation of microbiological methods, with a view to achieving regulatory compliance.
  • In the present study, a genome-wide RNA interference screen was combined with an extensive biochemical analysis and quantitative proteomics to better understand the regulation of the heat-shock response (HSR) upon thermal stress. The usage of an endoribonuclease-prepared small interfering RNA (esiRNA) library represented a simple and efficient way to perform RNAi with minimal off-target effects. In the screening experiments novel positive and negative modulators of the stress response were identified, including proteins involved in chromatin remodeling, transcription, mRNA splicing, DNA damage repair, and proteolytic degradation. The diversity of the identified regulators suggests that induction and attenuation of the HSR integrate signals from different cellular pathways and are rather multi-factorial processes than single gene/protein events. The modulator proteins are localized in multiple cellular compartments with the majority having their primary location in the nucleus. A protein-protein interaction analysis revealed a HSR regulatory network, with chromatin modifiers and nuclear protein quality control components occupying hub positions. These observations are supported by quantitative proteomics experiments, which showed specific stress-induced reorganizations of the nuclear proteome, including the transient accumulation of chaperones and proteasomal subunits.
    Moreover, we found that the acetyltransferase EP300 controls the cellular level of activatable HSF1. This involves acetylation of HSF1 at multiple lysines not required for function and results in stabilization of HSF1 against proteasomal turnover. Acetylation of functionally critical lysines during stress serves to fine-tune HSF1 activation. Finally, the nuclear proteasome system functions in attenuating the stress response by degrading activated HSF1 in a manner linked with the clearance of misfolded proteins.
  • Visit this page to download our infographic:
    http://www.vitaminsinmotion.com/fileadmin/data/pdf/Infographics/Vitamine-E-_-Cognition-11.jpg

    In our aging society, Alzheimer’s type dementia is a major concern. The disease can have a devastating impact on quality of life, with patients relying on caregivers for standard daily living activities. Whether it is memory impairment, deterioration, confusion or anger suffered by patients, this highly disruptive neurological disease demands attention.

    Vitamin E is vital for neural function and its deficiency can lead to neurological dysfunction, causing problems with co-ordination, balance and speech. It also has an antioxidant function in the brain – as a free radical scavenger and constituent of neural membranes, preventing the oxidation of lipids and PUFAs.

    Now, recent studies have found that maintaining a high level of vitamin E results in marked improvements for mental health and can be linked individually with a decrease in the onset of Alzheimer’s type dementia.

    Join our webinar and hear our speakers Prof. Maurice Dyksen and DSM’s Dr. Manfred Eggersdorfer and Jacob Bauly present their latest findings on vitamin E and its potential role in curbing the onset of Alzheimer’s disease.
  • In the present study, a genome-wide RNA interference screen was combined with an extensive biochemical analysis and quantitative proteomics to better understand the regulation of the heat-shock response (HSR) upon thermal stress. The usage of an endoribonuclease-prepared small interfering RNA (esiRNA) library represented a simple and efficient way to perform RNAi with minimal off-target effects. In the screening experiments novel positive and negative modulators of the stress response were identified, including proteins involved in chromatin remodeling, transcription, mRNA splicing, DNA damage repair, and proteolytic degradation. The diversity of the identified regulators suggests that induction and attenuation of the HSR integrate signals from different cellular pathways and are rather multi-factorial processes than single gene/protein events. The modulator proteins are localized in multiple cellular compartments with the majority having their primary location in the nucleus. A protein-protein interaction analysis revealed a HSR regulatory network, with chromatin modifiers and nuclear protein quality control components occupying hub positions. These observations are supported by quantitative proteomics experiments, which showed specific stress-induced reorganizations of the nuclear proteome, including the transient accumulation of chaperones and proteasomal subunits.
    Moreover, we found that the acetyltransferase EP300 controls the cellular level of activatable HSF1. This involves acetylation of HSF1 at multiple lysines not required for function and results in stabilization of HSF1 against proteasomal turnover. Acetylation of functionally critical lysines during stress serves to fine-tune HSF1 activation. Finally, the nuclear proteasome system functions in attenuating the stress response by degrading activated HSF1 in a manner linked with the clearance of misfolded proteins.
  • The way that physicians want and need to consume information is changing, almost to the point of being unrecognisable from the tried and tested methods of yesteryear, Working in conjunction with Ashfield Healthcare this event brings together Medical Futurist Dr Bertalan Meskó, Dr Partha Kar, Consultant Endocrinologist, Portsmouth Hospitals NHS Trust, with Ruth Herman and Nigel Campbell of Ashfield, which recently launched the Medical Education Future Forum and will be presenting insights from this unique programme.

    Taking place on the 21st May at 12.30 (UK), 13.30 (EU), 07.30 (E. US) and moderated by pharmaphorum's CEO Paul Tunnah, the debate will centre on three key questions,

    Why and how are physicians changing the way they receive information?
    What are the trends and technologies shaping the landscape of medical communication?
    What are the implications of this for pharma (with examples)?
  • Visit this page to download our infographic:
    http://www.vitaminsinmotion.com/fileadmin/data/pdf/Infographics/Vitamine-E-_-Cognition-11.jpg

    In our aging society, Alzheimer’s type dementia is a major concern. The disease can have a devastating impact on quality of life, with patients relying on caregivers for standard daily living activities. Whether it is memory impairment, deterioration, confusion or anger suffered by patients, this highly disruptive neurological disease demands attention.

    Vitamin E is vital for neural function and its deficiency can lead to neurological dysfunction, causing problems with co-ordination, balance and speech. It also has an antioxidant function in the brain – as a free radical scavenger and constituent of neural membranes, preventing the oxidation of lipids and PUFAs.

    Now, recent studies have found that maintaining a high level of vitamin E results in marked improvements for mental health and can be linked individually with a decrease in the onset of Alzheimer’s type dementia.

    Join our webinar and hear our speakers Prof. Maurice Dyksen and DSM’s Dr. Manfred Eggersdorfer and Jacob Bauly present their latest findings on vitamin E and its potential role in curbing the onset of Alzheimer’s disease.
  • Life sciences companies need to make better use of the insights that real world data (RWD) can provide in order to improve market access, sales and market growth strategies – and ultimately to improve the applicability of new and existing therapeutics for patients. Insights come not just from the multiple sources of RWD available, but from advanced analytics that highlight the effectiveness of a treatment by geographic area, and link healthcare providers, institutions and patients to relevant and meaningful outcomes.

    This one-hour event will take a hands-on approach – detailing how insights derived from RWD (and collaboratively with other sources) are enabling all elements of the life science industry to do things better.

    Insights experts Robin Munro and Christian Marcazzo will deliver case studies on how RWD can help life science companies in:

    Sales and Marketing – incorporate RWD and evidence into segmentation, targeting, and engagement of physicians and institutions
    Commercial Effectiveness – measure commercial campaigns, and demonstrate the impact to the healthcare system
    Medical Affairs – find and engage medical education prospects and target appropriate healthcare authorities, healthcare professionals and payers, to improve quality of care and outcomes
    Public Affairs and Market Access – develop qualitative and quantitative insights to design education, advocacy and access-related campaigns within the healthcare ecosystem

    The event will also give an exclusive look at what can be achieved from combining data sources – using Diabetes in England as a case study, Zephyr has implemented novel methods to demonstrate an evidence-based approach to improving information sharing within sales teams and to engaging accounts and payers. We explore how patient outcomes from RWD can add value to commercial strategy.
  • Though single-use technology and the general use of disposables are widely accepted and applied both in process development, pilot plant and selected production processes, they are not in general a reasonable choice at any scale or application. Notably process chromatography is considered a critical unit operation regarding feasibility to single-use application with the chromatographic matrix assumed to be the typical cost driver. But is this really true? The answer to this quite ambivalent: it depends! Numerous young and innovative companies have developed new and/or alternative products which can help to significantly reduce the costs of goods, thus providing an interesting basis for single-use applications. After all, taking into account reasonable scales and suitable manufacturing targets, the doors have been opened widely due to the supply of appropriate low-cost matrices and feasible hardware.
  • How to Prepare and What to Ask of Your Suppliers:

    In an effort to thwart fraudulent medical manufacturing practices, the European Commission published a Commission Recommendation (2013/473/EU) focusing on the assessment and auditing practices of notified bodies in the field of medical devices.
    A particular emphasis in this Recommendation has been placed on unannounced audits. Unannounced audits are additional assessments by notified bodies of manufacturers and/or their critical material suppliers. Auditors commissioned by the notified body will be able to arrive on site without giving the manufacturer prior notice and proceed with inspection. Over 5,000 unannounced audits are expected this year alone and come in addition to the initial surveillance or renewal audits of a three-year certification cycle.

    Now is the time to make sure you and your supplier’s quality and supply chain management systems are in place and you have full transparency. Join us for this informational webinar discussing this trending regulatory standard and learn about what you and your suppliers should be doing to proactively prepare.
  • Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information about how patients, physicians and payers behave through the use of open source, social media and real world data. However, segmentation still lacks clear insight into why these stakeholders behave as they do – and therefore how best to change their behaviour.
    Working with behavioural change experts Hamell, this one hour live discussion will look at why current segmentation strategies are failing, and the importance of understanding what drives patient or customer behaviour. Using case studies, speakers will explore how segmenting by behavioural drivers can create advanced, effective strategies to change patient, customer and payer behaviour.
    This event will focus on three key areas:

    •The theory behind behavioural segmentation and how it challenges the status quo
    •Benefits of behavioural segmentation communication strategies and the problems answered by behavioural segmentation strategies
    •Behavioural segmentation in action: practical application of this approach
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Cell therapy is the fastest growing segment of regenerative medicine. Cell therapy is comprised of immune cell therapy and stem cell therapy, with stem cell therapy making up the largest part of this market: it is estimated that the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030.

    Many factors determine the rate at which the stem cell therapy market advances. It is driven by the success of stem cell treatments in curing life-threatening diseases such as cancer, heart diseases and neuromuscular diseases in the worlds aging populations. In contrast, stem cell market growth rate is hindered by manufacturing and regulatory concerns. For example, if only 20% of the 318 global late stage clinical trials are approved for release on the market, there will not be enough stem cell therapy manufacturing facilities to produce the 64 resulting products. This is due, in part, to funding concerns, the high cost of build-out as well as cGMP compliance, standardization of production processes, and ever changing industry regulations.

    Join us as we discuss these and other key topics.
  • Join us on July 29 for the webinar, "In vitro ADME CRO: New capabilities in transporter, enzyme inhibition, and enzyme induction evaluation."
  • This webinar will focus on operations and maintenance of the StatSpin Express 3 centrifuge. By performing simple inspections, routine maintenance and operating the centrifuges as described in this webinar, you can maximize your StatSpin Express 3 uptime and sustain your productivity.
  • Because of worldwide demographic changes a dramatic increase of the geriatric population is expected in the next decades. While pediatric drug delivery principles are becoming integrated into the development of new medicines, drug developers are less prepared to appropriately address the specific needs of this booming patient population. This webinar tries to give an overview about the possible drug delivery strategies addressing old age dependent differences. There will be specifically focused on how patient convenience and compliance can be improved, how disease specific drug delivery strategies can help geriatric patients, and how learnings from pediatric drug development can be used as a platform towards geriatric drug delivery.